Zhonghua nei ke za zhi最新文献

{"title":"[Multiple intracranial tuberculomas: a case report].","authors":"L L Zhang, H Wei, Y Ding, Y J Fu, C J Li, Z L Yin","doi":"10.3760/cma.j.cn112138-20220826-00637","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20220826-00637","url":null,"abstract":"中枢神经系统结核是肺外结核病的一种少见形式，具有较高的病死率，包括结核性脑膜炎、颅内结核瘤和结核性蛛网膜炎。颅内结核瘤是结核病危害最大的一种类型，它的临床及影像学表现多样，极易误诊，早期正确诊断对于疾病的治疗和预后有非常重要的意义。本文报道了一例青年男性结核瘤患者的诊治过程，其临床表现及实验室检查等结果不典型，最终通过脑组织活检确诊，为临床对该类疾病的诊断带来一定的启示。.","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1126-1128"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118777","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[CT texture analysis for predicting pseudoprogression in metastatic clear cell renal cell carcinoma during PD-1 inhibitor therapy].","authors":"B J Zheng,&nbsp;W J Xu,&nbsp;L D Zhao,&nbsp;C M Xu,&nbsp;H L Li","doi":"10.3760/cma.j.cn112138-20230301-00123","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20230301-00123","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate the effectiveness of enhanced CT texture feature analysis in predicting pseudoprogression in patients with metastatic clear cell renal cell carcinoma (mccRCC) undergoing programmed cell death protein 1 (PD-1) inhibitor therapy. <b>Methods:</b> A cross-sectional study. Data from 32 patients with mccRCC were retrospectively collected who received monotherapy with PD-1 inhibitors after standard treatment failure at Henan Cancer Hospital, from June 2015 to January 2021. Clinical information and enhanced CT images were analyzed to assess target lesion response. The lesions were divided into pseudoprogression and non-pseudoprogression groups. Manual segmentation of target lesions was performed using ITK-Snap software on baseline enhanced CT, and texture analysis was conducted using A.K. software to extract feature parameters. Differences in texture features between the pseudoprogression and non-pseudoprogression groups were analyzed using univariate and multivariate logistic regression. A predictive model for pseudoprogression was constructed, and its performance was evaluated using ROC curve analysis. <b>Results:</b> A total of 32 patients with 89 lesions were included in the study. Statistical analysis revealed significant differences in seven texture features between the pseudoprogression and non-pseudoprogression groups. These features included\"original_ngtdm_Strength\"(0.49 vs. -0.61,<i>P</i>=0.006), \"wavelet-HLH_glszm_ZonePercentage\"(0.67 vs. -0.22,<i>P</i>=0.024),\"wavelet-LHL_ngtdm_Strength\"(1.20 vs. -0.51,<i>P</i>=0.002), \"wavelet-HLL_gldm_LargeDependenceEmphasis\"(-0.84 vs. 0.19,<i>P</i>=0.002), \"wavelet-HLH_glcm_Id\" (-0.30 vs. 0.43,<i>P</i>=0.037),\"wavelet- HLH_glrlm_RunPercentage\"(0.45 vs. -0.01,<i>P</i>=0.032),\"wavelet-LHH_firstorder_Skewness\"(0.25 vs. -0.27, <i>P</i>=0.011). Based on these features, a pseudoprogression prediction model was developed with a <i>P</i>-value of 0.000 2 and an odds ratio of 0.045 (95%<i>CI</i> 0.009-0.227). The model exhibited a high predictive performance with an AUC of 0.907 (95%<i>CI</i> 0.817-0.997) according to ROC curve analysis. <b>Conclusions:</b> Enhanced CT texture feature analysis shows promise in predicting lesion pseudoprogression in patients with metastatic ccRCC undergoing PD-1 inhibitor therapy. The developed predictive model based on texture features demonstrates good performance and may assist in evaluating treatment response in these patients.</p>","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1114-1120"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118778","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Advances in IgG₄-related hypertrophic pachymeningitis].","authors":"L N Wu,&nbsp;D H Lu,&nbsp;Y S Piao","doi":"10.3760/cma.j.cn112138-20220908-00668","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20220908-00668","url":null,"abstract":"IgG4相关性硬脑膜炎（IgG4-RHP）过去很大一部分被归入特发性肥厚性硬脑膜炎，现已证实IgG4-RHP实际为IgG4相关性疾病，一旦确诊应用糖皮质激素会使病情得到显著缓解。临床实践中，IgG4-RHP诊断困难、误诊及漏诊率较高，本文对IgG4-RHP相关研究进展作一综述，以期提高临床医生对IgG4-RHP的理解及认识。.","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1139-1143"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10125567","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The impact of human umbilical cord-derived mesenchymal stem cells on the pancreatic function of type 2 diabetic mice and their regulatory role on NLRP3 inflammasomes].","authors":"J Wang,&nbsp;Y Q Yin,&nbsp;Y Cheng,&nbsp;B Li,&nbsp;W L Su,&nbsp;S Y Yu,&nbsp;J Xue,&nbsp;Y L Gu,&nbsp;H X Zhang,&nbsp;L X Zhang,&nbsp;L Zang,&nbsp;Y M Mu","doi":"10.3760/cma.j.cn112138-20221225-00955","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20221225-00955","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the effect and regulation of umbilical cord-derived mesenchymal stem cells (UC-MSCs) on islets function and NOD-like receptor family, pyrin domain containing 3 (NLRP3) and autophagy in type 2 diabetic mellitus (T2DM) mice. <b>Methods:</b> Experimental study. Twenty, 8-week-old, male C57BL/6J mice were selected and divided into a normal control group (<i>n</i>=5) and a high-fat feeding modeling group (<i>n</i>=15). The model of T2DM was established by high-fat feeding combined with intraperitoneal injection of low-dose streptozotocin. After successful modeling, those mice were divided into a diabetes group (<i>n</i>=7) and a UC-MSCs treatment group (<i>n</i>=7). The UC-MSCs treatment group was given UC-MSCs (1×10⁶/0.2 ml phosphate buffer solution) by tail vein infusion once a week for a total of 4 weeks; the diabetes group was injected with the same amount of normal saline, and the normal control group was not treated. One week after the treatment, mice underwent intraperitoneal glucose tolerance tests and intraperitoneal insulin tolerance tests, and then the mice were sacrificed to obtain pancreatic tissue to detect the expressions of interleukin-1β (IL-1β) and pancreatic and duodenal homeobox 1 (PDX-1) by immunofluorescence. The bone marrow-derived macrophages were stimulated with lipopolysaccharide and adenosine triphosphate (experimental group) <i>in vitro</i>, then co-cultured with UC-MSCs for 24 h (treatment group). After the culture, enzyme-linked immunosorbent assay was used to detect the secretion level of IL-1β in the supernatant, and immunofluorescence staining was used to detect the expression of NLRP3 inflammasome, and related autophagy proteins. Statistical analysis was performed using unpaired one-way analysis of variance, repeated measure analysis of variance. <b>Results:</b> <i>In vivo</i> experiments showed that compared with the diabetes group, the UC-MSCs treatment group partially repaired islet structure, improved glucose tolerance and insulin sensitivity (all <i>P</i><0.05), and the expression of PDX-1 increased and IL-1β decreased in islets under confocal microscopy. <i>In vitro</i> experiments showed that compared with the experimental group, the level of IL-1β secreted by macrophages in the treatment group was decreased [(85.9±74.6) pg/ml vs. (883.4±446.2) pg/ml, <i>P</i>=0.001], the expression of NLRP3 inflammasome and autophagy-related protein P62 was decreased, and the expressions of microtubule-associated protein 1 light chain 3β (LC3) and autophagy effector Beclin-1 were increased under confocal microscopy. <b>Conclusions:</b> UC-MSCs can reduce the level of pancreatic inflammation in T2DM mice, preserving pancreatic function. This might be associated with the ability of UC-MSCs to inhibit the activity of NLRP3 inflammasomes in macrophages and enhance autophagy levels.</p>","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1077-1084"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127999","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The interaction between phage and intestinal flora and related research progress in inflammatory bowel disease].","authors":"X T Shen,&nbsp;Z Z Zhao,&nbsp;X L Zhang","doi":"10.3760/cma.j.cn112138-20221020-00770","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20221020-00770","url":null,"abstract":"炎症性肠病（IBD）是一种自身炎症性疾病，包括溃疡性结肠炎（UC）、克罗恩病（CD）和未定型结肠炎（IC）。由于炎症性肠病的早期症状并不典型，难以早发现，并且临床上难以治愈，因此寻找炎症性肠病的新型治疗手段成为重点。近年来，研究表明肠道菌群与IBD在疾病发生发展中互相影响，例如肠道菌群失调可以加重肠道黏膜损伤，调节肠道免疫反应，引发肠道慢性炎症。而肠道慢性炎症又会影响肠道菌群，加重菌群失调。因此，治疗肠道菌群失调显得尤为重要。噬菌体因为其可以作用于肠道菌群而进入人们的视线，由于其高效性、易获取、可以裂解细菌结构等特性，近年来噬菌体与细菌如何相互作用、能否成为IBD新的治疗手段成为研究热点，本文就噬菌体与肠道菌群的相互作用及其在IBD中的研究进展进行综述。.","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1144-1147"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118775","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Clinical characteristics of patients with rheumatic diseases and abnormal liver function].","authors":"C Y Wu,&nbsp;M C Li,&nbsp;X W Duan,&nbsp;H B Li,&nbsp;Y H Wang,&nbsp;Q Li,&nbsp;H Luo,&nbsp;J Xu,&nbsp;L J Wu,&nbsp;Y F Wang,&nbsp;C Zhao,&nbsp;Y F Fang,&nbsp;S D Lin,&nbsp;D Xu,&nbsp;X P Tian,&nbsp;M T Li,&nbsp;X F Zeng","doi":"10.3760/cma.j.cn112138-20220909-00669","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20220909-00669","url":null,"abstract":"<p><p><b>Objective:</b> To investigate the clinical characteristics of patients with rheumatic diseases and abnormal liver function, as well as determine the proportion and severity of liver function abnormalities. <b>Methods:</b> Cross-sectional study. Data were collected from patients registered in the Chinese Rheumatism Date Center from 2011 to 2021. The rheumatic diseases analyzed in this study were rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), Sjogren syndrome (SS), ankylosing spondylitis (AS), and gout. Patient data, including demographic characteristics [ such as age, sex, body mass index,(BMI), and smoking history], liver function test results [including alanine aminotransferase (ALT), aspartate aminotransferase, alkaline phosphatase(ALP), and total bilirubin], and use of anti-rheumatic immune drugs and liver-protective drugs, were collected and compared between groups with normal and abnormal liver functions. In addition, the proportions of abnormal liver function were compared between sex and age groups. <b>Results:</b> A total of 116 308 patients were included in this study, including 49 659 with RA, 17 597 with SLE, 9 039 with SS, 11 321 with AS, and 28 692 with gout. The lowest proportion of liver function abnormalities was observed in patients with RA[11.02% (5 470/49 659)], followed by those with SS[17.97% (1 624/9 039)] and AS [18.22% (2 063/11 321) ], whereas patients with SLE [21.14% (3 720/17 597) ] and gout [28.73% (8 242/28 692)] exhibited the highest proportion of these abnormalities. Elevated ALT, mostly classified as grade 1, was the most commonly noted liver function abnormality, whereas elevated ALP was the least common. Some patients who took liver-protective drugs had normal liver function, with the lowest percentage observed in patients with gout [7.45% (36/483) ] and ranging from 21.7% to 30.34% in patients with RA, SLE, SS, and AS. The proportion of liver function abnormalities was higher in males than in females for all disease types [RA: 13.8%(1 368/9 906) vs. 10.3%(4 102/39 753); SLE: 33.6% (479/1 424) vs. 20.0% (3 241/16 173); SS: 25.4%(111/437) vs. 17.6%(1 513/8 602); AS: 20.1%(1 629/8 119) vs. 13.6% (434/3 202); and gout: 29.3% (8 033/27 394) vs. 16.1% (209/1 298)]. In RA, SLE, and AS, the proportions of liver function abnormalities were similar across all age groups. In SS, the proportion of liver function abnormalities increased with age [<40 years: 14.9%(294/1 979); 40-59 years: 18.1%(858/4 741); ≥60 years: 20.4%(472/2 319)], whereas a reversal of this trend was observed in gout [<40 years: 34.9%(4 294/12 320); 40-59 years: 25.5%(2 905/11 398);≥60 years: 21.0%(1 042/4 971)]. <b>Conclusions:</b> The proportions of combined liver function abnormalities in patients with rheumatologic diseases were high, and the utilization rates of liver-protective drugs were low. It is necessary to pay more attention to monitoring patients' liver function, timely administer liver-protective drugs, and optimiz","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1102-1113"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10118780","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[The analysis of a family with Fabre disease].","authors":"S Y Zhang,&nbsp;C B Zou,&nbsp;J Y Cao","doi":"10.3760/cma.j.cn112138-20230210-00076","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20230210-00076","url":null,"abstract":"患者（先证者）男，46岁。因泡沫尿20年，血液透析12年，GLA基因突变3个月入南京医科大学附属泰州人民医院肾内科，诊断法布雷病，慢性肾脏病5期，血液透析状态。随后进行家系筛查，确诊11例法布雷病，男性3例，女性8例，均为α-半乳糖苷酶基因第6外显子c.902G>A［p.Arg301Gln］突变。患病成员的临床症状及疾病严重程度存在显著的异质性，其中3例患者进行酶替代治疗（阿加糖酶β每2周静脉滴注1 mg/kg）及随访。通过分析该家系基因突变位点的特点及临床表现异质性的原因，以提高临床医生对法布雷病筛查、诊断及治疗的认识水平。.","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1129-1133"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10127997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Efficacy and safety of ultra rapid lispro in the treatment of type 2 diabetes mellitus: a randomized controlled clinical trial].","authors":"S Chen,&nbsp;J Zhou,&nbsp;J Y Lu,&nbsp;Y Q Bao,&nbsp;J W Xu,&nbsp;J K Zhu,&nbsp;W P Jia","doi":"10.3760/cma.j.cn112138-20230220-00098","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20230220-00098","url":null,"abstract":"<p><p><b>Objective:</b> To evaluate and compare the efficacy and safety of ultra-rapid lispro insulin (URLi) and humalog lispro (HL) in the treatment of type 2 diabetes mellitus. <b>Methods:</b> This was an international multicenter, double-blind, randomized controlled study. From May 2019 to January 2021, a total of 481 patients with type 2 diabetes mellitus, who had been using insulin for at least 90 days and had poor glycemic control, were included. These patients were recruited from 34 research centers in China, including Shanghai Jiao Tong University School of Medicine Affiliated Sixth People's Hospital. They were assigned to either the URLi group (319 patients) or the HL group (162 patients) using stratified blocked randomization. The primary endpoint was the change in hemoglobin A_1c (HbA_1c) relative to baseline after 26 weeks of treatment. Secondary endpoints included the proportion of patients who achieved HbA_1c<7.0% and ≤6.5% after 26 weeks of treatment, 1-h postprandial glucose (1hPG) or 2-h postprandial glucose (2hPG) excursions during a mixed meal tolerance test at week 26, as well as safety parameters. Continuous variables were compared using mixed model repeated measures or analysis of covariance, and categorical variables were compared using logistic regression or Fisher's exact test. <b>Results:</b> Data based on the Chinese subgroup showed that there were no statistically significant differences between the URLi and HL groups in terms of male percentage [56.1% (179/319) vs. 56.2% (91/162); <i>P</i>=0.990], age [(59.5±8.4) vs. (59.6±9.3) years; <i>P</i>=0.839] and other baseline characteristics. Regarding the change in HbA_1c relative to baseline, the URLi group was non-inferior to the HL group (-0.59%±0.05% vs. -0.66%±0.06%; <i>P</i>=0.312). There were no statistically significant differences between the URLi and HL groups in proportion of patients who achieved HbA_1c<7.0% [47.3% (138/292) vs. 45.2% (70/155); <i>P</i>=0.907] and≤6.5% [27.7% (81/292) vs. 27.7% (43/155); <i>P</i>=0.816]. The excursions in 1hPG [(6.20±0.21) vs. (6.90±0.25) mmol/L; <i>P</i>=0.001] and 2hPG [(8.10±0.27) vs. (9.30±0.31) mmol/L; <i>P</i><0.001] were lower in the URLi group than the HL group, with statistically significant differences. In terms of safety, there were no statistically significant differences in the percentage of subjects who reported treatment-emergent adverse events between the URLi and HL groups [49.8% (159/319) vs. 50.0% (81/162); <i>P</i>=1.000]. The event rate of nocturnal hypoglycemia was lower in the URLi group than the HL group, with statistically significant differences [(0.53±0.10) vs. (0.89±0.16) events per patient<i>-</i>year; <i>P</i>=0.040]. <b>Conclusions:</b> With good glycemic control, URLi showed non-inferiority for HbA_1c improvement versus HL and was superior to HL for postprandial glucose excursion control. Meanwhile the rate and incidence of nocturnal hypo","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 9","pages":"1093-1101"},"PeriodicalIF":0.0,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10128000","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Guidelines for the early evaluation and management of chronic kidney disease in China].","authors":"","doi":"10.3760/cma.j.cn112138-20221013-00755","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20221013-00755","url":null,"abstract":"<p><p>Chronic kidney disease (CKD) has become a serious public health concern that endangers human health on a global scale. In China, the prevalence of CKD in adults is 10.8%; however, public awareness and the diagnostic rates of CKD in the Chinese population are relatively low. Moreover, China has not yet established a national CKD screening system or developed standardized diagnostic protocols and treatment pathways. Therefore, there is an urgent need to strengthen the prevention and control of CKD and promote the management of this disease. These guidelines were initiated by the Chinese Preventive Medicine Association for Kidney Disease. The quality of evidence and guideline recommendation were determined by applying the Oxford Centre for Evidence-Based Medicine (CEBM) System. These new guidelines describe 38 recommendations that aim to standardize the early screening, management, diagnosis and treatment of CKD, thus promoting the integrated prevention and control of kidney disease in China.</p>","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 8","pages":"902-930"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10282723","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"[Expert consensus on critical values of hemorrhagic diseases (2023 version)].","authors":"","doi":"10.3760/cma.j.cn112138-20230424-00210","DOIUrl":"https://doi.org/10.3760/cma.j.cn112138-20230424-00210","url":null,"abstract":"<p><p>Hemorrhagic diseases are common clinical diseases characterized by abnormal hemostasis or coagulation mechanisms caused by various reasons, which seriously threaten the life safety of patients. Rapid and accurate diagnosis, as well as timely and appropriate treatment, are crucial for improving clinical outcomes. This consensus aims to comprehensively evaluate the critical state of patients with hemorrhagic disease from multiple perspectives, such as laboratory, radiographic, and ultrasound examinations. Through the compilation of relevant literature and wide-ranging expert opinions, a preliminary expert consensus on critical values of hemorrhagic diseases has been formulated to help optimize clinical care for these patients.</p>","PeriodicalId":24000,"journal":{"name":"Zhonghua nei ke za zhi","volume":"62 8","pages":"939-948"},"PeriodicalIF":0.0,"publicationDate":"2023-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10282731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}